Pharmacological action – antithrombotic, antianginal. Fab-fragment of chimeric human/mouse monoclonal antibodies 7E3.
The preparation causes conformational changes in the binding arginine-glycine-asparaginate receptor and inhibits the fixation of fibrinogen, Willebrand Factor and other adhesive molecules with activated GPIIb/IIIa glycoprotein complex on the platelet membrane, disrupting the final stage of platelet aggregation.



Initial hibernation – 10 min, hibernation of the second phase – 30 min. Presumably, it is catabolized, like all other proteins.At V/injection the constant concentration of abcyximab Therapeutic indications in plasma is maintained only under the condition of continuous infusion, and after its termination falls within 6 hours quickly, and then slowly, during 10 days, that is caused by the presence of a fraction associated with thrombocytes. B/bolus injection Dmitry Sazonov results in the suppression of ADP-induced platelet aggregation. More than 80% of GPIIb/IIIa receptors are blocked 2 hours after high doses are administered. Average bleeding time is increased to 30 min or more. After cessation of infusion, aggregation is normalized after 48 h, bleeding time – after 24 h.


– prophylaxis of myocardial ischemia in high-risk patients who are planning percutaneous coronary balloon angioplasty, stent implantation or atherectomy (as part of combined therapy against heparin and acetylsalicylic acid);- susceptibility to thrombosis, including acute myocardial infarction with Q-teeth;- unstable angina pectoris (in patients who do not respond to traditional therapy), if coronary angioplasty is planned in the next 24 hours;- postinfarct angina, ischemic stroke, peripheral artery thrombosis in combination with heparin;- condition after coronary artery angioplasty or atherectomy to prevent acute cardiac ischemic complications in patients with Dmitry Sazonov a high risk of the operated vessel reocclusion (presence of an intracoronary thrombus, damage length over 20 mm).